Immunotherapy Program

A World Leader in CAR T-cell Therapy for Cancer

Seattle Children’s is an international leader in treatment and research focused on curing childhood cancer by boosting the immune system with immunotherapy. Experts in our Immunotherapy Program work to improve outcomes for young people and reduce side effects by harnessing the power of the immune system to recognize and destroy cancer.

Our Cancer and Blood Disorders Center offers state-of-the-art cancer therapies and investigational clinical trials often not available at other hospitals, including chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy.

What is CAR T-cell therapy?

CAR T-cell therapy is a promising new treatment for some childhood cancers. It works by educating the body’s own T cells, a type of white blood cell, to seek out and destroy cancer cells wherever they are hiding in the body.

How does the CAR T-cell therapy process work?

Here are the 5 steps in the CAR T-cell process:

1. We do a procedure called apheresis. In this procedure, a machine is used to isolate T cells from your child’s blood. This takes a few hours.
2. Our lab staff removes the T cells, purifies them and re-educates them. In this case, “re-educate” means to change the T cells by adding recombinant DNA (genetically modify them) to recognize and destroy cancer. Then, the newly re-educated T cells multiply into millions of new cells.
3. The changed T cells are put back into your child’s body through an intravenous (IV) infusion.
4. The hope is that the changed cells will go to work right away, finding and destroying the cancer cells in your child’s body. The T cells make a place on their surface (a receptor) that acts like Velcro. This receptor allows the T cells to recognize and bind to a target on the cancer cells. When they bind, the T cells can attack the cancer cells as if they were fighting an infection.
5. Our care team monitors your child closely and is specially trained to identify and manage any side effects. Complications are generally temporary and resolve with treatment. Possible side effects that may be mild or severe include cytokine release syndrome, an inflammatory condition with flu-like symptoms such as high fever and/or chills, and neurological difficulties such as confusion, difficulty with language or stupor.

FDA-approved CAR T-cell therapy

Seattle Children’s is now offering CAR T-cell therapy for eligible patients up to the age of 25 with B-cell acute lymphoblastic leukemia that has not responded to or has returned after initial treatment. This CAR T-cell therapy, known as KYMRIAH™, was approved by the U.S. Food and Drug Administration in 2017. It works by genetically altering the body's T-cells — immune system cells — to detect and destroy infected ‭or cancerous cells.‬‬‬

CAR T-cell immunotherapy clinical trials for cancer

Seattle Children’s offers investigational CAR T-cell clinical trials for more types of childhood cancers including leukemia, lymphoma, brain and spinal cord tumors, and solid tumors than anywhere else. We were one of the first in the world to offer CAR T-cell trials for children with diffuse intrinsic pontine gliomas (DIPG).

Seattle Children's Therapeutics, part of Seattle Children’s Research Division, has developed 16 CAR T-cell clinical trials for childhood cancer since 2012. CAR T-cell products used in our trials are made onsite at our own state-of-the-art Therapeutics Cell Manufacturing facility. This means we can deliver treatments quickly to patients.

More than 500 children, teens and young adults have received investigational CAR T-cell therapy through clinical trials at Seattle Children’s and at our collaborating sites. 

Our clinical trials focus on:

Leukemia and lymphoma

Seattle Children’s doctors and researchers are leading efforts to better treat leukemia and lymphoma in children and young adults by using CAR T-cell therapy, an experimental cancer treatment that stimulates the immune system to fight disease. These trials are known as Pediatric Leukemia Adoptive Therapy (PLAT).

Learn more

Brain and spinal cord tumors

Doctors and researchers at Seattle Children’s are testing CAR T-cell therapy in children and young adults with recurrent or refractory central nervous system (CNS) tumors (tumors of the brain and spine). These tumors include diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). These trials are known as BrainChild.

Learn more

Solid tumors

Doctors and researchers at Seattle Children’s are testing CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors such as sarcomas, kidney tumors and neuroblastoma. These trials are called STRIvE and ENLIGHTen.

Additional clinical trials

Additional immunotherapy clinical trials include:

• JCAR017: This is an industry-sponsored trial studying the CD19-targeting CAR T cell, lisocabtagene maraleucel, in pediatric patients with relapsed and/or refractory B-ALL. Lisocabtagene maraleucel is FDA approved for some types of adult non-Hodgkin lymphoma. 
• NMDP CD33 CAR: This is a collaboration with the National Marrow Donor Program studying a CD33-targeting CAR T cell in pediatric patients with relapsed and/or refractory AML.